Pentagon mandates testosterone screening for troops
Analysis based on 9 articles · First reported Sep 02, 2026 · Last updated Sep 03, 2026
The policy is unlikely to have a direct impact on major defense contractors or the broader stock market, as it primarily affects internal military health procedures. However, it could influence the healthcare sector, particularly companies involved in testosterone replacement therapies and diagnostic testing, by potentially increasing demand for such services.
On September 2, 2026, the United States — United States Department of Defense issued detailed clinical guidelines for a mandatory testosterone deficiency screening policy for active-duty and reserve service members aged 30 and older. The policy, announced by Defense Secretary Pete Hegseth in July, takes effect immediately and aims to improve military readiness by identifying and managing hormonal and energy-availability issues. Men aged 30 and older will receive mandatory testosterone blood tests during regular health assessments, while younger men will be tested only on request or if clinicians identify warning signs. Women will be screened for symptoms of hormonal dysregulation, such as fatigue and disrupted menstrual cycles, but will not undergo routine testosterone blood tests. The guidelines also outline when off-label testosterone prescription is appropriate for postmenopausal women with low sexual desire. The United States — Defense Health Agency released the guidelines, which call testosterone levels a critical biological marker for warfighter readiness. Medical experts have raised concerns about the lack of scientific evidence for universal screening and the potential for unnecessary or harmful treatment. The United States — Food and Drug Administration plans to hold a meeting of experts in mid-September to discuss the medical use of testosterone.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard